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SHORT COMMUNICATION
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'Division ofOncology, Department ofInternal Medicine I, Vienna University Medical School, Waehringer Guertel 18-20, A-1090
Vienna, and2Department ofBiopharmacy, Institutefor Pharmaceutical Chemistry, University of Vienna, Waehringerstrasse 10,
A-1090 Vienna, Austria.
Summary The potential for a pharmacokinetic interaction between epirubicin and the second-generation
multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with
advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribu-
tion of epirubicin from the serum and altered disposition might, in fact, explain the increased level of
myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.
A common form of multidrug resistance (MDR) in human
cancer is associated with the expression of the mdrl gene,
which appears to be a major impediment to more successful
cancer chemotherapy (Pastan, 1987). Whereas a large number
ofdrugs, the prototype ofwhich is verapamil, have now been
identified which can modify the MDR phenotype in vitro,
target plasma levels predicted from tissue culture data are
commonly non-achievable or too toxic in vivo (Plumb et al.,
1990). An atttractive alternative MDR modulating agent cur-
rently undergoing clinical investigation, is the D-isomer of
the marketed drug verapamil (a racemic DL mixture), which
is characterised by equal resistance reverting potential but at
least 3-fold less cardiovascular activity (Bisset et al., 1991).
Preliminary data of clinical trials involving D-verapamil
(DVPM) in the treatment of colorectal (Kornek et al., 1992)
and pancreatic cancer (unpublished data) suggest a possible
enhancement of anthracycline-related myelotoxicity. The
potential for a pharmacokinetic interaction between DVPM
and epirubicin has therefore been investigated in a pilot
study.
Patients and methods
Six patients (four male, two female; median age 57 years)
with histologically confirmed advanced colorectal cancer were
studied. All patients had a World Health Organization
(WHO) performance status of 1 and had normal renal and
hepatic function as judged by standard biochemical
parameters, though hepatic sonography revealed presence of
liver metastases in three. No patient was taking any drugs
likely to affect hepatic blood flow or the activity of the
hepatic mono-oxygenase system, and no patient had received
chemotherapy within 4 weeks prior to study entry. Patients
were treated with a single dose of epirubicin (90mgm2
body surface administered by intravenous bolus injection)
with or without DVPM with one or other of the first two
courses ofcytotoxic therapy, as defined by simple randomisa-
tion using a central number list derived from tables. Treat-
ment was repeated at 4-week intervals provided
hematological parameters were satisfactory. In the case of
combined treatment, oral DVPM (Knoll AG, Ludwigshafen,
Germany) was taken at a dose of 300 mg every 6 h for three
consecutive days, and epirubicin was administered 1 h after
the morning dose of DVPM on day 2. Intermittent venous
sampling was conducted thereafter for 8 h. Serum levels of
epirubicin were analysed blinded to the treatment using solid-
phase extraction and reversed-phase high-performance liquid
chromatography (HPLC) (Czejka, 1988). D-verapamil and its
metabolite D-norverapamil were determined by an HPLC
assay with fluorescence detection (Buehler). All plasma con-
centration data used for pharmacokinetic calculations were
mean values of duplicate analysis. All patients gave informed
consent before entering the study, in accordance with the
guidelines of the ethics committee of the University of
Vienna.
Results
Paired kinetic data were available for all six subjects. The
mean (± s.d.) epirubicin concentration-time decay curves are
shown in Figure 1, whereas the pharamacokinetic parameters
for individual patients are summarised in Table I. These data
suggest that combined treatment with DVPM causes a reduc-
tion of the initial CO-level of epirubicin, the area under the
curve (AUC) and the biological half-life, while the volume of
distribution at steady-state is unchanged, and the total
plasma clearance is increased. Although we can not exclude
errors in significancy for statistical analysis due to the small
number of patients involved in this cross-over study, there
appear to exist significant differences in CO(P = 0.015), and
terminal half-life (P = 0.003). Since anthracyclines are
eliminated very slowly from the central compartment (app-
roximately 30 h), and the observed time interval in our study
was only 8 h, the apparent significant difference in terminal
half-life seems to be related mainly to the distribution and
not to the elimination phase. The change of the hybride
constant A, representing the distribution phase, in fact, was
of borderline significance (P = 0.07).
Plasma levels of both DVPM (2.18 ± 1.56 Lml ') and D-
norverapamil (1.57 ± 0.99tml'1) measured at the time of
epirubicin administration showed considerable interpatient
variability, though values were within the range described
previously for a daily dose of 1200 mg DVPM (Bisset et al.,
1991). When the parent compound and active metabolite
(Merry et al., 1989) levels are combined, a mean value of
3.74 Lml ' (range, 1.76 to 7.27 gml-') was achieved.
The incidence of non-hematologic side effects was com-
parable in these patients for each course of chemotherapy,
independent of DVPM administration. The mean nadir
granulocyte count (day 14 of the cycle), however, tended to
be lower for the combined treatment with DVPM
(1,734Jl1-') than for epirubicin alone (2,873 -l') (P<0.05,
Mann Whitney U-test).
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Figure 1 Concentration-time curve for intravenous administra-
tion of epirubicin alone (0) or after treatment with oral D-
verapamil (-). Each point represents the mean value (± s.d.) for
the six subjects.
Discussion
It would appear from this pilot study on a small number of
patients that there is the potential for a significant change in
the pharmacokinetics of epirubicin caused by DVPM. Our
data suggest that combining epirubicin with DVPM might
enhance the distribution of epirubicin from the serum and
alter its disposition. Based on chromatograms, a change of
the metabolic pattern of the anthracycline in serum through
DVPM could be ruled out (data not shown).
It seems noteworthy that a pharmacokinetic interaction
has been reported previously for verapamil and doxorubicin
(Kerr et al., 1986). The rather divergent influence of the
racemic mixture verapamil used in that study on various
kinetic parameters of the anthracycline might at least par-
tially be explained by different pharmacological properties of
the D-and L-isomer, including electrophysiologic effects
(Echizen et al., 1985), protein binding, volume of distribution
and clearance (Eichelbaum et al., 1984), as well as first-pass
metabolism (Vogelsang et al., 1984). Another factor to be
considered is that the dose of D-verapamil in this study is
significantly higher than the dose of racemic verapamil in the
study of Kerr and co-workers.
Whether the enhanced level ofmyelotoxicity noticed in this
pilot as well as our clinical phase II studies of DVPM plus
anthracyclines (including more than 30 colorectal and panc-
reatic cancer patients by now) can soley be explained through
the described pharmacokinetic interaction, or whether an
inhibition of drug efflux from normal cells plays an addi-
tional role, remains uncertain. Nevertheless, if DVPM is
taken further as a resistance modulator, the pharmacokinetic
interaction with epirubicin (and probably also with other
anthracyclines) should be further determined and be taken
into consideration in the design and analysis of clinical
studies with respect both to toxicity and to tumour re-
sponse.
The authors greatfully acknowledge the technical assistance of Mr D.
Schoebel, Department of Biochemistry, Knoll-AG.
Table I Pharmacokinetic parameters for epirubicin ± D-verapamil
AUC Biological Clearance Vdss Initial Co
(ngml-'h-' half-life (h) (I h-') (I) (lgml-')
Subject E E+ DVPM E E + DVPM E E + DVPM E E + DVPM E E + DVPM
1 male 1826 849 3.9 3.8 70.0 166.8 327 590 11.9 4.4
2 male 3402 1512 6.5 2.7 31.3 96.8 243 212 19.3 10.4
3 female 2129 315 4.4 0.4 58.9 982.5 301 65 15.5 5.5
4 male 3076 1689 7.1 3.0 32.0 106.6 308 361 9.5 6.0
5 female 6778 6833 5.8 5.1 21.2 44.2 164 186 6.4 4.7
6 male 11510 3257 6.7 1.2 15.6 55.3 122 154 9.1 8.2
Mean 4768 2409 5.7 2.7 38.1 242.0 244 261 11.9 6.5
SD 3737 2384 1.3 1.7 21.6 365.0 84 187 4.7 2.3
pa 0.10 0.003 0.10 NS 0.015
E = epirubicin alone; E + DVPM = epirubicin + D-verapamil. ap_level of probability (Paired Student's t-test).
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